Related Experiment Videos
Optison (FS069) disrupts the blood-brain barrier in rats
G Mychaskiw1, A E Badr, R Tibbs
1Department of Anesthesiology, University of Mississippi Medical Center, Jackson, Mississippi 39216-4505, USA. gmychaskiw@anesthesia.umsmed.edu
Anesthesia and Analgesia
|September 27, 2000
Summary
Optison, an echocardiographic contrast agent, may disrupt the blood-brain barrier in rats. This effect appears dependent on Optison dosage, warranting further investigation into its implications for congenital heart disease evaluation.
Area of Science:
- Neuroscience
- Cardiology
- Pharmacology
Background:
- Optison is an echocardiographic contrast agent used for cardiac imaging.
- Its utility in congenital heart disease evaluation is recognized.
- Potential direct cerebral circulation introduction necessitates safety assessment.
Purpose of the Study:
- To evaluate the effects of Optison on the blood-brain barrier (BBB).
- To determine if Optison administration impacts BBB integrity in cerebral circulation.
- To assess the dose-dependency of any observed BBB disruption.
Main Methods:
- Anesthetized Sprague-Dawley rats underwent carotid artery injection of Optison at varying dosages.
- Evans blue dye was administered at different time points post-injection to mark BBB disruption.
- Gross and histological examination of brain tissue was performed.
Main Results:
- Optison administration resulted in observable disruption of the blood-brain barrier.
- The extent of BBB disruption was found to be dose-dependent on Optison.
- The specific mechanism of disruption remains undetermined.
Conclusions:
- Optison may compromise blood-brain barrier integrity.
- The observed effect is linked to Optison dosage.
- Further research is required to understand the pathological consequences and underlying mechanisms.